CLINICAL RESEARCH: HEART RHYTHM DISORDERS
Verapamil Versus Digoxin and Acute Versus Routine Serial Cardioversion for the Improvement of Rhythm Control for Persistent Atrial Fibrillation
Martin E.W. Hemels, MD*,
Trudeke Van Noord, MD*,
Harry J.G.M. Crijns, MD ,
Dirk J. Van Veldhuisen, MD, FACC*,
Nic J.G.M. Veeger, MSc ,
Hans A. Bosker, MD ,
Ans C. P. Wiesfeld, MD*,
Maarten P. Van den Berg, MD*,
Adelita V. Ranchor, PhD|| and
Isabelle C. Van Gelder, MD*,*
* Department of Cardiology, University Medical Center Groningen, University of Groningen, Groningen, the Netherlands
University Hospital, Maastricht, the Netherlands
Trial Coordination Center, Groningen, the Netherlands
Rijnstate Hospital, Arnhem, the Netherlands
|| Northern Center for Health Care Research, Groningen, the Netherlands
Manuscript received January 25, 2006;
revised manuscript received April 10, 2006,
accepted May 2, 2006.
* Reprint requests and correspondence: Dr. Isabelle C. Van Gelder, Department of Cardiology, Thoraxcenter, University Medical Center Groningen, University of Groningen, P.O. Box 30.001, 9700 RB Groningen, the Netherlands. (Email: I.C.van.Gelder{at}thorax.umcg.nl).
OBJECTIVES: The VERDICT (Verapamil Versus Digoxin and Acute Versus Routine Serial Cardioversion Trial) is a prospective, randomized study to investigate whether: 1) acutely repeated serial electrical cardioversions (ECVs) after a relapse of atrial fibrillation (AF); and 2) prevention of intracellular calcium overload by verapamil, decrease intractability of AF.
BACKGROUND: Rhythm control is desirable in patients suffering from symptomatic AF.
METHODS: A total of 144 patients with persistent AF were included. Seventy-four (51%) patients were randomized to the acute (within 24 h) and 70 (49%) patients to the routine serial ECVs, and 74 (51%) patients to verapamil and 70 (49%) patients to digoxin for rate control before ECV and continued during follow-up (2 x 2 factorial design). Class III antiarrhythmic drugs were used after a relapse of AF. Follow-up was 18 months.
RESULTS: At baseline, there were no significant differences between the groups, except for beta-blocker use in the verapamil versus digoxin group (38% vs. 60%, respectively, p = 0.01). At follow-up, no difference in the occurrence of permanent AF between the acute and the routine cardioversion groups was observed (32% [95% confidence intervals (CI)] 22 to 44) vs. 31% [95% CI 21 to 44], respectively, p = NS), and also no difference between the verapamil- and the digoxin-randomized patients (28% [95% CI 19 to 40] vs. 36% [95% CI 25 to 48] respectively, p = NS). Multivariate Cox regression analysis revealed that lone digoxin use was the only significant predictor of failure of rhythm control treatment (hazard ratio 2.2 [95% CI 1.1 to 4.4], p = 0.02).
CONCLUSIONS: An acute serial cardioversion strategy does not improve long-term rhythm control in comparison with a routine serial cardioversion strategy. Furthermore, verapamil has no beneficial effect in a serial cardioversion strategy.
|
Abbreviations and Acronyms
| | AF = atrial fibrillation | | CI = confidence interval | | ECV = electrical cardioversion | | INR = international normalized ratio | | IRAF = immediate reinitiation of atrial fibrillation | | LV = left ventricle/ventricular | | NYHA = New York Heart Association | | SR = sinus rhythm |
|
This article has been cited by other articles:

|
 |

|
 |
 
S. Ahmed, M. Rienstra, H. J. G. M. Crijns, T. P. Links, A. C. P. Wiesfeld, H. L. Hillege, H. A. Bosker, D. J. A. Lok, D. J. Van Veldhuisen, I. C. Van Gelder, et al.
Continuous vs Episodic Prophylactic Treatment With Amiodarone for the Prevention of Atrial Fibrillation: A Randomized Trial
JAMA,
October 15, 2008;
300(15):
1784 - 1792.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|